# reload+after+2024-01-23 06:46:10.548843
address1§12780 El Camino Real
city§San Diego
state§CA
zip§92130
country§United States
phone§858 617 7600
fax§858 617 7602
website§https://www.neurocrine.com
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL  Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
fullTimeEmployees§1400
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Kevin C. Gorman Ph.D.', 'age': 65, 'title': 'CEO & Director', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 1902342, 'exercisedValue': 0, 'unexercisedValue': 66140656}, {'maxAge': 1, 'name': 'Mr. Matthew C. Abernethy', 'age': 43, 'title': 'Chief Financial Officer', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 1044134, 'exercisedValue': 0, 'unexercisedValue': 6447159}, {'maxAge': 1, 'name': 'Mr. Darin M. Lippoldt Esq.', 'age': 57, 'title': 'Chief Legal Officer & Corporate Secretary', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 921011, 'exercisedValue': 2982335, 'unexercisedValue': 6897830}, {'maxAge': 1, 'name': 'Mr. Kyle W. Gano Ph.D.', 'age': 50, 'title': 'Chief Business Development and Strategy Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 921518, 'exercisedValue': 2171968, 'unexercisedValue': 25934578}, {'maxAge': 1, 'name': 'Dr. Eiry Wyn Roberts M.D.', 'age': 59, 'title': 'Chief Medical Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 1035080, 'exercisedValue': 0, 'unexercisedValue': 12121826}, {'maxAge': 1, 'name': 'Dr. Jude  Onyia Ph.D.', 'age': 59, 'title': 'Chief Scientific Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 621660, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Jane  Sorensen', 'title': 'Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Julie S. Cooke', 'age': 57, 'title': 'Chief Human Resources Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Eric S. Benevich', 'age': 58, 'title': 'Chief Commercial Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 804999, 'exercisedValue': 295525, 'unexercisedValue': 7038861}, {'maxAge': 1, 'name': 'Mr. David Warren Boyer', 'age': 44, 'title': 'Chief Corporate Affairs Officer', 'yearBorn': 1979, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§1
compensationRisk§4
shareHolderRightsRisk§3
overallRisk§2
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
exDividendDate§820195200
payoutRatio§0.0
beta§0.331
priceToSalesTrailing12Months§7.296604
currency§USD
dateShortInterest§1702598400
forwardEps§4.64
pegRatio§3.23
exchange§NMS
quoteType§EQUITY
shortName§Neurocrine Biosciences, Inc.
longName§Neurocrine Biosciences, Inc.
firstTradeDateEpochUtc§832858200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§2532fb18-868f-3936-991c-d8060c56d55f
gmtOffSetMilliseconds§-18000000
targetHighPrice§170.0
targetLowPrice§100.0
targetMeanPrice§136.85
targetMedianPrice§137.5
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§26
quickRatio§2.188
earningsGrowth§0.188
grossMargins§0.6724
ebitdaMargins§0.20622998
trailingPegRatio§None
